Richard Jones

Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany.

HBM Partners AG (HBM-P) was established in 2001 as an independent provider of investment advisory services with headquarters in Zug, Switzerland. HBM-P's field of expertise comprises global human medicine, biotechnology, medical technology and related sectors. The firm primarily advises HBM BioVentures AG and HBM BioCapital via their Cayman Islands-based, wholly-owned subsidiary, HBM Partners (Cayman) Ltd., which acts as the investment manager for the HBM funds. They rely on the services of an external consultant to analyze investment opportunities in the US.

Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ.

Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto.

Part of Merck KGaA, Biovation Ltd. is a British company that develops proprietary pharmaceutical and diagnostic agents. The company is based in Aberdeen, UK. Biovation was acquired by Merck KGaA on October 01, 2000 for $29.28 million.

Part of Roche Holding AG, Roche Diagnostics GmbH is a German company that develops innovative medicines, treatments, and diagnostics. The company is based in Mannheim, Germany. The CEOs of the company are Claudia Fleischer, Claus Haberda, Clemens Schmid. Roche Diagnostics was acquired by Roche Holding AG on January 01, 1999.

B·R·A·H·M·S GmbH engages in the development and manufacture of novel diagnostic testing procedures. Its products include B·R·A·H·M·S PCT (Procalcitonin), MR-proADM (Mid-regional proadrenomedullin), Copeptin proAVP, Neopterin, and KRYPTOR Instruments. The company was founded in 1994 and is headquartered in Hennigsdorf, Germany.

Definiens AG is a holding company, which engages in the development and market of biomedical imaging and data analysis software solutions. The firm specializes in the design and manufacture of imaging software suites for drug discovery, development, and diagnostics applications. It engages in the custom image analysis projects for the biopharmaceutical industry, spanning drug discovery, translational research, and clinical research. It offers image analysis processing, integration and deployment, planning, and consulting services. The company was founded by Gerd Binnig in 1994 and is headquartered in Munich, Germany.

Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT.

PolyTherics Ltd. develops biomedical polymers for therapeutic applications. The company was founded by Antony Godwin, Sunil Shaunak and Steve Brocchini in 2001 and is headquartered in Babraham, the United Kingdom.

Neurelis, Inc. operates as a specialty pharmaceutical company. It is organized to license, develop and commercialize product candidates for the treatment of central nervous system disorders with a focus on the acute treatment of epilepsy and anxiety episodes. The company was founded by Craig C. Chambliss and David F. Hale in 2007 and is headquartered in San Diego, CA.

Boehringer Ingelheim RCV GmbH & Co. KG develops and supplies biotherapeutic proteins, plasmid DNA and antibody fragments. The company was founded in 1885 by Albert Boehringer and is headquartered in Vienna, Austria.

Abzena (Cambridge) Ltd. provides antibody engineering and immunogenicity screening services. The company was founded in 2004 and is headquartered in Babraham, the United Kingdom.

Part of HBM Partners AG, HBM Healthcare Investments (Cayman) Ltd. provides healthcare services. The company is based in George Town, Cayman Islands. Andreas Wicki has been the CEO of the company since 2001.

iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium.

in.vent DIAGNOSTICA GmbH engages in the development and production of in vitro diagnostics. It specializes in the procurement, processing and distribution of human biological materials. The firm also manufactures long-term control materials for internal quality assurance purposes which are used in medical laboratory routines. The comapny products include InQualiCheck, serum and plasma, tissue and proteins and antibodies. in.vent DIAGNOSTICA was founded in 1997 and is headquartered in Hennigsdorf, Germany.

Oxford Genetics Ltd. produces modular DNA plasmids for biological research. Its products include DNA systems, kits, and cell lines. The company was founded by Ryan Cawood and Leonard Seymour on April 28, 2011 and is headquartered in Oxford, the United Kingdom.

SphingoTec GmbH develops method for prediction, prevention, intervention of cancer, cardiovascular disease and kidney function. The firm specializes in biomarker discovery and acute care diagnostics. The company was founded by Andreas Bergmann in 2002 and is headquartered in Hennigsdorf, Germany.

InVivo BioTech Services GmbH engages in contract manufacturing organization dedicated to the development and production of monoclonal antibodies and expression of recombinant proteins. The company was founded by Andreas Bergmann in 1998 and is headquartered in Hennigsdorf, Germany.

Part of Reaction Biology Corp., Bioassay Labor für biologische Analytik GmbH is a contract service organization based in Heidelberg, Germany. The German company specializes in the development and validation of bioassays for pharmaceutical potency testing, with services performed under GMP and GLP certification to meet regulatory guidance for pre-market and on-market products. The company was founded by Andreas Bergmann and the CEOs are Axel Hohenstein and Sven-Michael Cords. Bioassay Labor für biologische Analytik GmbH was acquired by Reaction Biology Corp. on December 02, 2022.

4teen4 Pharmaceuticals GmbH engages in the research and development in diagnostic and therapeutics bio markets. The company was founded by Andreas Bergmann in 2013 and is headquartered in Hennigsdorf, Germany.

MS Unisea GmbH & Co. KG provides sea and coastal freight transportation services. The private company is based in Haren, Germany. The CEOs of the German company are Andreas Bergmann, Bernhard Held.

MS Unistream GmbH & Co. KG provides warehousing services. The private company is based in Haren, Germany. The CEOs of the German company are Andreas Bergmann, Bernhard Held.

PhotonPharma, Inc. is a company that is developing a personalized therapeutic cancer vaccine called Innocell. The company is based in Fort Collins, CO, at the Research Innovation Center of Colorado State University. The vaccine is designed using autologous tumor tissue and a photochemical inactivation platform that uses riboflavin and UV light to render tumor cells incapable of replication while still being able to metabolize, express proteins, present antigen, and stimulate immune recognition and response mechanisms. The company has demonstrated the ability of this technology to prevent metastatic tumor formation, reduce the growth of tumors, and stimulate cellular immune response pathways in preclinical development animal models. The company was founded in 2018 by Raymond Goodrich, and the CEO is Alan S. Rudolph.

Mahzi Therapeutics is a private biotechnology company that focuses on genetic therapies for rare genetic neurodevelopmental disorders. The company was founded by Yael Weiss and is based in San Mateo, CA. The company unites patient and family groups, academic researchers, diagnostic companies, other industry members, and its internal team of experts to develop therapies for patients with these serious diseases. Mahzi's team is experienced in all aspects of biopharmaceutical research, development, and manufacturing and is driven to make a difference in the lives of patients with rare genetic diseases. Yael Weiss has been the CEO since incorporation.

PAM Theragnostics GmbH is a German biotech company that aims to develop a reliable tool for early diagnosis of Alzheimer's disease. PAM Theragnostics is based in Hennigsdorf, DE. The company's long-term vision is to provide safe and cost-effective therapy for Alzheimer's patients. Andreas Bergmann is a visionary who has launched and co-founded several successful biotech companies, including Sphingotec GmbH, 4teen4, and Adrenomed AG. The company was founded by Andreas Bergmann, who has been the CEO since incorporation.